Likewise, there are state agencies and startup's alike working on pre-natal genetics screening that basically tries to identify from pre-natal samples particular markers (SNPs) known for Down Syndrome, Tay-Sachs etc. Not to mention people who submit their samples to find interesting markers from 23andme.
I'd love to hear more from folks in the field what they think the next big application of computational biology, clinical genomics will be. Obviously, there has been a lot of mixed opinion regarding both on the consumer side (FDA banning 23andme from making broad statements of users having a higher-probability of cancer due to outdated and controversial data) and research side (has Human Genome Project since its completion in the early 2000's yielded a significant gene to target compound to drug on the market?)
More practically, Illumina (https://www.google.com/finance?q=NASDAQ%3AILMN&ei=af5xVYHoB4...) has more than 10x in the past 6 years, riding the wave of demand and growth of next-gen sequencing technology. If Cloud Computing is hailed as the sequencer's of the next phase in the biotech revolution, what stocks should I buy now to take advantage of it?